mTOR at the Transmitting and Receiving Ends in Tumor Immunity
Cancer is a complex disease and a leading cause of death worldwide. Immunity is critical for cancer control. Cancer cells exhibit high mutational rates and therefore altered self or neo-antigens, eliciting an immune response to promote tumor eradication. Failure to mount a proper immune response lea...
Main Authors: | Yakir Guri, Thierry M. Nordmann, Jason Roszik |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-03-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2018.00578/full |
Similar Items
-
TOX Acts as a Tumor Suppressor by Inhibiting mTOR Signaling in Colorectal Cancer
by: Mengdi Yang, et al.
Published: (2021-04-01) -
Editorial: Targeting Metabolism in Cancer Immunotherapy
by: Jason Roszik, et al.
Published: (2018-09-01) -
Prognostic significance and tumor-immune infiltration of mTOR in clear cell renal cell carcinoma
by: Na Li, et al.
Published: (2021-08-01) -
Advanced Research of mTOR and Lung Carcinoid Tumors
by: Zixuan ZHANG, et al.
Published: (2013-01-01) -
The Role of Mechanistic Target of Rapamycin (mTOR) Complexes Signaling in the Immune Responses
by: Ghada A. Soliman
Published: (2013-06-01)